GI Innovation, Inc. (358570.KQ)

KRW 9790.0

(-4.39%)

Long Term Debt Summary of GI Innovation, Inc.

  • GI Innovation, Inc.'s latest annual long term debt in 2023 was 2.9 Billion KRW , down -16.35% from previous year.
  • GI Innovation, Inc.'s latest quarterly long term debt in 2024 Q2 was - KRW , down 0.0% from previous quarter.
  • GI Innovation, Inc. reported annual long term debt of 3.47 Billion KRW in 2022, down -4.48% from previous year.
  • GI Innovation, Inc. reported annual long term debt of 3.63 Billion KRW in 2021, up 62.19% from previous year.
  • GI Innovation, Inc. reported quarterly long term debt of 2.81 Billion KRW for 2024 Q1, down 0.0% from previous quarter.
  • GI Innovation, Inc. reported quarterly long term debt of 2.9 Billion KRW for 2023 FY, down -16.35% from previous quarter.

Annual Long Term Debt Chart of GI Innovation, Inc. (2023 - 2019)

Historical Annual Long Term Debt of GI Innovation, Inc. (2023 - 2019)

Year Long Term Debt Long Term Debt Growth
2023 2.9 Billion KRW -16.35%
2022 3.47 Billion KRW -4.48%
2021 3.63 Billion KRW 62.19%
2020 2.24 Billion KRW -97.97%
2019 110.6 Billion KRW 0.0%

Peer Long Term Debt Comparison of GI Innovation, Inc.

Name Long Term Debt Long Term Debt Difference
HLB Co., Ltd. 17.93 Billion KRW 83.807%
iNtRON Biotechnology, Inc. 258.29 Million KRW -1024.299%
BINEX Co., Ltd. 5.57 Billion KRW 47.942%
Bioneer Corporation 12.5 Billion KRW 76.768%
Anterogen.Co.,Ltd. - KRW -Infinity%
MEDIPOST Co., Ltd. 6.99 Billion KRW 58.484%
CrystalGenomics, Inc. 29.88 Billion USD 90.284%
Helixmith Co., Ltd 151.68 Million KRW -1814.562%
Chabiotech Co.,Ltd. 95.06 Billion KRW 96.945%
Medy-Tox Inc. 1.22 Billion KRW -136.899%
Peptron, Inc. 4.5 Billion KRW 35.467%
Amicogen, Inc. 70.65 Billion KRW 95.89%
Genexine, Inc. 22.68 Billion KRW 87.197%
HLB Therapeutics Co.,Ltd. 1.84 Billion KRW -57.81%
LegoChem Biosciences, Inc. 528.37 Million KRW -449.613%
ALTEOGEN Inc. 1.24 Billion KRW -132.459%
PharmaResearch Co., Ltd. 970.71 Million KRW -199.161%
SillaJen, Inc. 8.13 Billion KRW 64.306%
JETEMA, Co., Ltd. 60 Billion KRW 95.16%
OliX Pharmaceuticals,Inc 35.36 Billion KRW 91.788%
Genomictree Inc. 97.51 Million KRW -2877.99%
MedPacto, Inc. 1.68 Billion KRW -72.146%
D&D Pharmatech 5.12 Billion KRW 43.288%
EASY BIO,Inc. 30 Billion KRW 90.32%